Kineta Inc
NASDAQ:KA
If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
This alert will be permanently deleted.
Kineta Inc
Kineta, Inc. is a clinical-stage biotechnology company, which develops immunotherapies for cancer patients. The company is headquartered in Seattle, Washington and currently employs 40 full-time employees. The company went IPO on 2016-02-11. The firm is focused on discovering and developing differentiated immunotherapies that address the challenges with current cancer therapy. The firm's immuno-oncology focused PiiONEER Platform aims at developing fully human antibodies to address the major mechanisms of cancer immune resistance, such as immuno-suppression, exhausted T cells and poor tumor immunogenicity. Its pipeline of assets developed through the PiiONEER Platform includes KVA12123, a monoclonal antibody (mAb) immunotherapy targeting V-domain Ig suppressor of T cell activation (VISTA), an anti-CD27 agonist mAb immunotherapy and an anti-CD24 antagonist mAb immunotherapy discovery program. VISTA blocks immunotherapy to address the problem of immunosuppression in the tumor microenvironment. The company is developing anti-CD27 agonist mAb immunotherapy to address the problem of exhausted T cells in the tumor microenvironment.
Kineta, Inc. is a clinical-stage biotechnology company, which develops immunotherapies for cancer patients. The company is headquartered in Seattle, Washington and currently employs 40 full-time employees. The company went IPO on 2016-02-11. The firm is focused on discovering and developing differentiated immunotherapies that address the challenges with current cancer therapy. The firm's immuno-oncology focused PiiONEER Platform aims at developing fully human antibodies to address the major mechanisms of cancer immune resistance, such as immuno-suppression, exhausted T cells and poor tumor immunogenicity. Its pipeline of assets developed through the PiiONEER Platform includes KVA12123, a monoclonal antibody (mAb) immunotherapy targeting V-domain Ig suppressor of T cell activation (VISTA), an anti-CD27 agonist mAb immunotherapy and an anti-CD24 antagonist mAb immunotherapy discovery program. VISTA blocks immunotherapy to address the problem of immunosuppression in the tumor microenvironment. The company is developing anti-CD27 agonist mAb immunotherapy to address the problem of exhausted T cells in the tumor microenvironment.
